Cargando…

The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma

SIMPLE SUMMARY: In the last decade, proteasome inhibitors (PIs) have become a standard for the treatment of multiple myeloma (MM). As a consequence of the pleiotropic effects of PIs on various signaling pathways, synergistic or additive activities with other anti-myeloma therapies have been identifi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paradzik, Tina, Bandini, Cecilia, Mereu, Elisabetta, Labrador, Maria, Taiana, Elisa, Amodio, Nicola, Neri, Antonino, Piva, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000754/ https://www.ncbi.nlm.nih.gov/pubmed/33799793 http://dx.doi.org/10.3390/cancers13061235

Ejemplares similares

Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma
por: Bandini, Cecilia, et al.
Publicado: (2023)

Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines
por: Mereu, Elisabetta, et al.
Publicado: (2023)

Genomic Instability in Multiple Myeloma: A “Non-Coding RNA” Perspective
por: Taiana, Elisa, et al.
Publicado: (2021)

Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins
por: Taiana, Elisa, et al.
Publicado: (2022)

Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma
por: Todoerti, Katia, et al.
Publicado: (2021)

Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology
por: Raimondi, Lavinia, et al.
Publicado: (2020)

Long Non-Coding RNAs in Multiple Myeloma
por: Nobili, Lucia, et al.
Publicado: (2018)

The heterogeneous landscape of ALK negative ALCL
por: Mereu, Elisabetta, et al.
Publicado: (2017)

Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity
por: Amodio, Nicola, et al.
Publicado: (2018)

Jagged Ligands Enhance the Pro-Angiogenic Activity of Multiple Myeloma Cells
por: Palano, Maria Teresa, et al.
Publicado: (2020)

Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma
por: Ronchetti, Domenica, et al.
Publicado: (2020)

Proteasome Inhibitors for the Treatment of Multiple Myeloma
por: Ito, Shigeki
Publicado: (2020)

New proteasome inhibitors in the treatment of multiple myeloma
por: Hungria, Vania Tietsche de Moraes, et al.
Publicado: (2019)

Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma
por: Ambrosio, Francesca Alessandra, et al.
Publicado: (2023)

Epigenetic Regulation of Mitochondrial Quality Control Genes in Multiple Myeloma: A Sequenom MassARRAY Pilot Investigation on HMCLs
por: D’Aquila, Patrizia, et al.
Publicado: (2021)

A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma
por: Ronchetti, Domenica, et al.
Publicado: (2018)

DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome
por: Todoerti, Katia, et al.
Publicado: (2021)

Notch signaling deregulation in multiple myeloma: A rational molecular target
por: Colombo, Michela, et al.
Publicado: (2015)

Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
por: Merin, Noah M., et al.
Publicado: (2014)

Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
por: Ramirez, Krista G.
Publicado: (2017)

Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma
por: Ronchetti, Domenica, et al.
Publicado: (2016)

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
por: Acosta-Alvear, Diego, et al.
Publicado: (2015)

LncRNA NEAT1 in Paraspeckles: A Structural Scaffold for Cellular DNA Damage Response Systems?
por: Taiana, Elisa, et al.
Publicado: (2020)

Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients
por: Calura, Enrica, et al.
Publicado: (2015)

Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma
por: Kubiczkova, Lenka, et al.
Publicado: (2014)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma
por: Heynen, Guus J. J. E., et al.
Publicado: (2022)

Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
por: Haney, Staci L., et al.
Publicado: (2022)

Recent Advances on the Pathobiology and Treatment of Multiple Myeloma
por: Amodio, Nicola
Publicado: (2021)

Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents
por: Kurtin, Sandra E., et al.
Publicado: (2013)

Pulmonary Nocardiosis in a Multiple Myeloma Patient Treated with Proteasome Inhibitors
por: Mendonca, Nikolai P., et al.
Publicado: (2016)

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma
por: Qiang, Ya-Wei, et al.
Publicado: (2018)

The Effects of Proteasome Inhibitors on Telomerase Activity and Regulation in Multiple Myeloma Cells
por: Shalem-Cohavi, Naama, et al.
Publicado: (2019)

Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
por: Chen, John H., et al.
Publicado: (2017)

Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma
por: Zhang, Hua, et al.
Publicado: (2022)

Metabolic Alterations in Multiple Myeloma: From Oncogenesis to Proteasome Inhibitor Resistance
por: Weir, Philip, et al.
Publicado: (2023)

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
por: Gu, Yanyan, et al.
Publicado: (2020)

In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma
por: Di Martino, Maria Teresa, et al.
Publicado: (2013)

Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing
por: Agnelli, Luca, et al.
Publicado: (2019)

P847: BIOLOGICAL AND MOLECULAR CHARACTERIZATION OF IN SILICO IDENTIFIED PUTATIVE INHIBITORS OF PARASPECKLE ASSEMBLY WITH POTENTIAL ANTI-MULTIPLE MYELOMA ACTIVITY.
por: Traini, Valentina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8d5p9d3b0smb6luj92ftgk9nhn